Dignitana report
2015-08-26 20:35, Edited at: 2015-08-28 09:17Please note: Community posts are written by its members and not by Redeye’s research department. As a reader you’re always encouraged to critically analyze the content.
The Dignitana report today made the share fall more than 8 %. To some extent I understand the sellers, but I still find Dignitana a profitable case for a long- and midterm investor - and awaits the FDA-approval of the Dignicap sytem.
The report can be found under IR at www.dignitana.se
In the light of the China share-unrest, a fall of more than 8 % is understandable, but compared to the mid- and long-term possiblities of Dignitana the fall must be seen as temporaraly.
The FDA-approval is still a heavy trigger and the opening of the Chinese market, can swiftly chage the image of a low turnover, and slow sales in Europe and Asia.
Read my full evaluation of the report at www.svenskeaktier.dk, and learn why I perfer Dignitana and other Swedish start-up share.